A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s immune system to produce defence proteins, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent coverage when vaccinated four weeks before birth
- Maternal antibodies transferred through the placenta protect newborns from birth
- Protection achievable with two-week gap before premature birth
- Vaccination during the third trimester still offers significant infant protection
Strong evidence from current research
The efficacy of the pregnancy RSV vaccine has been demonstrated through a extensive research programme conducted across England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s practical effectiveness. The study’s findings have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scope of this study provides healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the great majority being infants whose mothers had not been given the vaccination. This stark contrast emphasises the vaccine’s essential role in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Study methodology and scope
The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospital admissions. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology measured actual clinical results rather than controlled laboratory conditions, providing practical evidence of how the vaccine works when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection produces deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe effectively. Parents frequently observe their babies visibly struggling, their chests rising whilst they work to get adequate oxygen into their damaged lungs. Whilst most newborns recover with palliative treatment, a small but significant group succumb from RSV-related complications annually, making prevention through vaccination a vital health service imperative for defending the youngest and most vulnerable members of society.
- RSV causes inflammation in lungs, resulting in severe breathing difficulties in babies
- Nearly 50% of newborns catch the virus in their first few months of life
- Symptoms vary between mild colds to life-threatening chest infections needing hospital treatment
- Over 20,000 UK infants need serious hospital treatment for RSV annually
- Small numbers of infants succumb to RSV complications each year in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the value of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies via the placenta.
The communication from health authorities remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These geographical variations reflect variations in medical facilities, engagement approaches, and community involvement initiatives, though the overall statistics shows consistently strong protection regardless of geographical location.
- NHS trusts launching diverse outreach initiatives to reach expectant mothers
- Inconsistencies across regions in vaccine uptake rates across England demand focused enhancement
- Regional health providers tailoring initiatives to align with local requirements and situations
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness delivers tangible benefits for families across the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the rollout of this safeguarding intervention, the 80% drop in admissions means thousands of infants spared from severe infection. Parents no longer face the upsetting situation of watching their newborns labour to breathe or struggle to eat, symptoms that mark critical RSV illness. The vaccine has substantially transformed the terrain of neonatal lung health, giving expectant mothers a preventative option to shield their youngest infants during those vital initial period.
For families like that of Malachi, whose severe RSV infection led to severe brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab highlights the profound consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to expectant mothers in their final trimester, converting what was once an inevitable seasonal threat into a manageable health risk.